. 2023 Apr-Jun;35(2):217–225. doi: 10.5935/2965-2774.20230289-en

Table 2.

Effect of CytoSorb® on secondary outcomes

	Control group			CytoSorb® group
Norepinephrine levels (ug/kg/min)
Study	NE T0	NE 48 hours	p value	NE T0	NE 48 hours	p value
Hawchar et al.⁽¹⁰⁾	0.43 [0.19 - 0.64]	0.25 [0.08 - 0.65]	NR	0.54 [0.20 - 1.22]	0.16 [0.07 - 0.48]	0.016
Akil et al.⁽¹⁸⁾	0.83 ± 0.16	0.38 ± 0.11	0.05	0.603 ± 0.08	0.009 ± 0.005	0.0001
C-reactive protein levels (mg/L)
Study	CRP T0	CRP 48 hours	p value	PCR T0	PCR 48 hours	p value
Hawchar et al.⁽¹⁰⁾	307.4 ± 116.7	189.9 ± 48.5	NS	238.1 ± 95.5	169.54 ± 86.4	NS
Akil et al.⁽¹⁸⁾	27.2 ± 2.9	22.6 ± 3.1	0.31	35 ± 5	12 ± 3	0.002
Procalcitonin levels (ng/mL)
Study	PCT T0	PCT 48 hours	p value	PCT T0	PCT 48 hours	p value
Hawchar et al.⁽¹⁰⁾	13.2 [7.6 - 47.8]	9.2 [3.8 - 44.2]	NR	20.6 [6.5 - 144.5]	5.6 [1.9 - 54.4]	0.004
Akil et al.⁽¹⁸⁾	13.14 ± 9.7	8.14 ± 5.9	0.68	15.6 ± 5.4	2.71 ± 1.5	0.03
*Predicted versus* observed mortality**
Study	Observed mortality	Predicted mortality	p value	Observed mortality	Predicted mortality	p value
Brouwer et al.⁽¹⁹⁾	51%	67,9%	0,035	47,8%	74,5%	< 0,001
Rugg et al.⁽¹¹⁾	47,6%	65,7%	NR	21,4%	85,7%	NR

NE - norepinephrine; CRP - C-reactive protein; PCT - procalcitonin.